Predict your next investment

HEALTHCARE | Biotechnology
akesobio.com

See what CB Insights has to offer

Founded Year

2012

Stage

IPO | IPO

Total Raised

$215.55M

Date of IPO

4/24/2020

About Akeso Biopharma

Akeso Biopharma (9926.HK) is a biotechnology company that subjects antibody candidates to 3D analysis simulations.

Akeso Biopharma Headquarter Location

6 Shennong Road Torch Development Zone

Zhongshan, Guangdong, 528437,

China

+86 0760-8987 3998

Latest Akeso Biopharma News

The Top 25 Healthcare Technology CEOs of Asia for 2020

Nov 17, 2020

. Asia’s healthtech market has continued its rapid growth with a select group of leaders and their companies standing out for their demonstrated operational expertise and skill at innovation. This year’s awardees were selected in large part based on nominations submitted by their colleagues and peers as well as further research into the depth of their experience and their ability to bring transformative products and services to market. In a challenging time for the healthcare sector across the board, these CEOs have made a substantial impact. Not only have they fostered productive and dynamic workplaces, they have also stood at the forefront of cutting-edge technological development. As the industry braces to face new and existing challenges, which have only been exacerbated by the global pandemic, the strategic decision-making of these CEOs helps to solidify their companies as leaders in Asia and beyond. Please join us in recognizing the achievements of The Top 25 Healthcare Technology CEOs of Asia for 2020. Location: Shanghai, China David Chang is the Chief Executive Officer of WuXi AppTec, the leading global pharmaceutical, biopharmaceutical, and medical device company. WuXi AppTec covers the development cycle through five core operations: small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics. In his role, Chang provides strategic scientific and operational leadership to the company’s global cell and gene therapy R&D and manufacturing services. He brings with him extensive experience in the health industry with a demonstrated history of working in biotechnology. Prior to his position at WuXi AppTec, Chang held several management and top leadership positions. Most recently, he was the corporate vice president and head of global cell therapy at Celgene Corporate for two years. Prior to that, he served for five years at Roche as a vice president and finally global head. Chang also worked at Genetec for over seven years as director and senior director, moving on from being a director at Biogen for six years prior. He was also a leader at BASF Bioresearch. Chang earned his Bachelor of Science degree in chemical engineering from the National Taiwan University, and PhD in biochemical engineering from the Massachusetts Institute of Technology. Location: Mumbai, India Peter DeYoung is the Chief Executive Officer of Piramal Global Pharma and a member of the Piramal Pharma Limited Board. Piramal Global Pharma is comprised of the Piramal Pharma Solutions (PPS) and Piramal Critical Care (PCC) business units. PPS is a contract development and manufacturing organization offering end-to-end development and manufacturing solutions across the drug life cycle. PCC is a leading global player in the hospital genetics segment and is the world’s third largest producer of inhaled anesthetics with a marketing presence in over 1,000 countries. In his instrumental role with both entities, DeYoung steers strategy and oversees the growth drivers for success. DeYoung worked his way up to the top role after spearheading several leadership mandates at the Piramal Group, including as the CEO of Piramal Critical Care and President of Life Sciences. Previously, DeYoung worked in various investing and consulting roles in healthcare in the U.S., Europe, and India. He worked at McKinsey & Company over two periods, first when he graduated from Princeton as a business analyst, and back again four years later as an engagement manager across New York and Mumbai. He held his final position with McKinsey & Company for just over three years before joining the Blackstone Group in Private Equity. During his time at McKinsey & Company, he was seconded by the company to the World Economic Forum in Geneva as part of the Global Health Initiative. DeYoung holds a Master of Business Administration degree from Stanford University and a Bachelor of Science degree in engineering from Princeton University. Location: Beijing, China John Oyler is the Founder and Chief Executive Officer of BeiGene, the leading fully integrated, global biopharmaceutical company transforming and improving treatment outcomes and access for patients with cancer worldwide. Since the company was founded in 2010, BeiGene has developed a number of promising compounds in its oncology pipeline that are being evaluated extensively in clinical trials throughout the world. With a collaborative spirit, BeiGene has developed high-quality drugs quicker by leveraging the collective strength of U.S. drug development expertise with access to the large patient population in China. The company boasts that it has no borders, with over 3,000 employees from Beijing to Basel. In addition to leading BeiGene, Oyler is also a Board Member of the Biotechnology Innovation Organization as of June 2019. Prior to BeiGene, he was the founder and CEO of BioDuro, a company he was with for four and a half years. He started that company following a top-level leadership tenure as the CEO of Galena from 2002 to 2004. He was also the president and founder of Telephia (previously Nielson Mobile) for almost five years. He earned his business expertise at McKinsey & Company where he worked as a consultant for five years before becoming the co-CEO of Genta. Oyler acquired a Bachelor of Mechanical Engineering degree from the Massachusetts Institute of Technology and a Master of Business Administration degree from Stanford University. Location: Mumbai, India Sanjiv Navangul has championed the mission of patient care while leading a host of global pharmaceutical companies to operational success. He has served on the board of Johnson & Johnson Pvt Ltd. India and Fulford India and held several leadership roles through his 30-year career as Managing Director of Janssen (Pharmaceutical Division of Johnson & Johnson) in India and South Asia, Managing Director of MSD Pharmaceuticals in Philippines and as Commercial Director of MSD in India and South Asia. As the CEO of BSV, Mr. Navangul is a ‘go-to-patient’ torch bearer for the biopharmaceutical company that is setting benchmarks in patient outcomes in the therapeutic areas of Women’s health, Critical Care and Emergency medicine. Earlier, he was instrumental in working on the access to multidrug-resistant tuberculosis treatment for Indian patients. Acknowledged by the industry for his mentorship, Mr. Navangul has served as the Vice President of OPPI (Organisation of Pharmaceutical Producers of India) from 2014 to 2019, Chairman of the Pharma committee of the American Chamber of Commerce and Chairman, Medical and Regulatory Committee of OPPI from 2016 to 2019. He is also a management committee member of the well-known Victoria Memorial School for the Blind, Mumbai. Location: Bangalore, India Shashank ND is the Co-Founder and Chief Executive Officer of Practo, a company that aims to be the single destination for consumers to have all their health needs met for themselves and their loved ones. Through Practo, users can find doctors, book appointments, chat online with practitioners, order medicines and lab tests, store health records, and even access health articles written by doctors. For healthcare providers, Practo provides them with a platform that connects with consumers in a way that provides a better patient experience, better patient results, and resources for growing their practice. Since founding the practice in 2012 with Co-Founder Abhinav Lal, he has driven the overall vision and direction for Practo, actively building the company’s disrupting products with a mission to improve healthcare and longevity. Today his company is considered one of the fastest-growing healthcare companies in the world, popularizing healthcare as a mainstream for start-up innovation. With over 200,000 healthcare providers on its platform and a presence in India, Singapore, the Philippines, Brazil, and Indonesia catering to companies in over 10 countries, Practo is certainly a company to watch under ND’s leadership. He is also a founder circle member of iSPIRIT, a think tank for the Indian software industry. He has been featured on the Forbes 30 Under 30 list of young influential people to watch, and the 2016 Fortune 40 Under 40 most promising business leaders in India. He has a Bachelor of Technology degree from the National Institutes of Technology. Location: Shanghai, China Alex Li is the President and Chief Executive Officer at United Imaging Healthcare Surgical, a role he has held for almost nine years. United Imaging Healthcare develops and produces a full portfolio of advanced medical imaging and radiotherapy equipment, offering medical IT and intelligent solutions. Founded in 2011, the company has subsidiaries and R&D centers across China, the U.S., and other parts of the world with around 3,300 employees globally. Currently, more than 3,000 hospitals worldwide are utilizing the company’s products. Li brings to United Imaging Healthcare over two decades of leadership experience at two of the world’s largest healthcare technology companies. Just before his current position, he was the R&D director for Philips in Changzhou-Wuxi-Suzhou for two years. Before that, he worked at General Electric for over a decade between China and Boston within the Edison Technical Leadership Program and was an engineering manager for the conglomerate. Active in the community, Li volunteers as an adjunct professor at Shanghai Jiao Tong University as well as the Huazhong University of Science and Technology. He acquired a Master of Science degree from SITP, Chinese Academy of Sciences. Li also has a Bachelor of Science degree from Fudan University, and a PhD in biomedical engineering from Dartmouth College. Location: Mumbai, India Dharmil Sheth is disrupting healthtech in India as the Co-Founder and Chief Executive Officer of PharmEasy. PharmEasy is India’s first healthcare ecosystem tailored to improve the lives of every stakeholder in the health cycle from patient, to doctor, pharmacy, pharmacist, diagnostic lab, and any other service provider in the process. The company started with a mission to ensure that patients undergoing treatment for chronic illness have easy access to medications. After its launch in 2015, PharmEasy was one of many start-ups delivering medicines online but quickly grew to be the largest platform in the business. With its innovative solutions, PharmEasy has more than doubled its business each year. Sheth is also the Founder and current President of Ekagrata, an organization that supports education and the growth and development of underprivileged youth. Prior to PharmEasy, Sheth founded 91streets, a company that is a shopping companion and marketing platform connecting customers to modern retailers for an elevated shopping experience. He gained experience for his businesses as a summer intern for MakeMyTrip.com and through working in business development for Techno Gravity Solutions. Sheth acquired a Bachelor of Engineering degree from K.J. Somaiya College of Engineering and a Master of Business Administration degree from the Institute of Management Technology, Ghaziabad. Location: Jakarta, Indonesia Jonathan Sudharta is the Chief Executive Officer and Co-Founder of Halodoc, the online healthcare start-up based in Indonesia. Halodoc revolves around solving a critical problem in medicine: how to allow hundreds of millions of people without proper access to clinics to receive attention from doctors and to get the diagnosis and drugs they require quickly and economically. Speaking of his company, a founding partner of the Gates Foundation’s Strategic Investment Fund shared, “someone is going to solve patient-centric, 21st century, primary healthcare and we think Halodoc has huge potential to do that.” Since its founding almost five years ago, 40 million people already use Halodoc’s app or website to connect with over 22,000 licensed doctors in Indonesia for online consultation. Patients are able to buy medicines through the app from one of more than 1,000 pharmacies that deliver medicines via motorcycle or scooter, all at an affordable price for both the consultation and medication. Catering to one of the fastest-growing internet nations with only two physicians per 10,000 people, Halodoc is truly solving the critical issue it is pursuing. Prior to founding his own company, Sudharta worked his way up from being a trainee for his father’s pharmaceutical company. Following this, he worked as a junior medical representative at Mensa for 13 years, rising through the company ranks before co-founding Halodoc. Sudharta studied commerce at Curtin University. Location: Bangalore, India A leader across many disciplines, Tushar Vashisht is the Co-founder and Chief Executive Officer of HealthifyMe. Founded in 2011 alongside Mathew Cherian and Sachin Shenoy, HealthifyMe’s vision is “to help Indians be healthier and fitter using online tools.” Today, the company is India’s first comprehensive calorie tracker and in 2019 he launched AI-powered Smart Plans recommended by the digital nutritionist “Ria,” which are informed by users’ habits and medical conditions. HealthifyMe has had four successful funding rounds and is a top-rated Indian start-up on the Google Play Store. Prior to founding HealthifyMe, Vashisht was an investment banker on Wall Street beginning as an intern for Black Rock before joining Deutsche Bank as a corporate finance analyst in San Francisco before relocating to Singapore. Just prior to starting HealthifyMe, he was the manager of project strategy for the UDAI, Government of India. It was there that he met many of the future board members and early investors of HealthifyMe. Vashisht has become a great advocate for better nutrition policies for Indians, giving presentations on the matter to Indian Prime Minister Narendra Modi and Russian President Vladimir Putin. Tushar first attended the Delhi College of Engineering and Netaji Subhas Institute of Technology before acquiring a Bachelor of Applied Science degree in computer science from the University of Pennsylvania. Location: Bangalore, India Vedam Ramprasad is the Chief Executive Officer of MedGenome Labs, the genomics-driven research and diagnostics company. With a company mission to improve global health by decoding the genetic information contained in an individual’s genome, Ramprasad’s role as CEO is to strengthen operations in the country, as well as focus on the company’s expansion to markets in Asia and Africa. Currently, MedGenome’s powerful genome solutions are credited to have accelerated the biomarker identification and discovery research of pharma and biotech companies. MedGenome provides unique access to genomics data with clinical and phenotypic data that offers insights into complex diseases at the genetic molecular level to facilitate research in personalized health. A scientist with several peer-reviewed publications under his belt, Ramprasad’s work has always been motivated by the drive to harness the power of genomics for providing better outcomes to patients. With over two decades of experience, Ramprasad has worked with medical research foundations Vision Research Foundation and Sankara Nethralaya, scientific equipment supplier Spinco Biotech, and genomics company SciGenome Labs. Ramprasad is also well regarded for launching critical genetic tests at affordable prices. He is considered one of the few scientists in India to have significantly contributed to the emergence of understanding the relevance of genetics in India. Ramprasad acquired his Master of Science degree and PhD from the Birla Institute of Technology and Science, Pilani. Location: Gurgaon, India A self-taught, serial entrepreneur, Deepak Sahni is the Founder and Chief Executive Officer of Healthians, the technology-led, asset-light, and direct to consumer healthcare service. The company aims to add ten healthy years to every Indian citizen’s life with a simple, effective, and modern approach, providing the largest at-home service offering affordable pathology testing. Healthians follows this with continuous health advice, consultation screening, and monitoring for improving health conditions, thus reducing travel time and the potential spread of illness in public spaces. Sahni is continuously adding to his 15 years of IT and healthcare marketing expertise to expand upon his personal vision to provide businesses of national value to India. Prior to Healthians, Sahni was the founder and director of SWT, a full-service web and digital marketing agency based in Gurgaon, India. It was known for being one of the largest healthcare digital services firms in India, working with over 70 hospitals, more than 350 doctors, and clinics across India, Dubai, Thailand, and the U.S. He was with SWT for seven years. He was also previously the co-founder of High Beam Global, a joint business in medical value travel and market research services. He exited this company after three and a half years. A highly celebrated pioneer and leader, Sahni has received many prestigious honors and awards, including being the Young Entrepreneur of the Year in India for 2016, receiving the 2015 Leaders Award for Health & Social Care Enterprise of the Year in 2016, and having Healthians be awarded Health & Wellness e-Retailer of the Year for 2015. Location: Bangalore, India Prashant Jhaveri is the Chief Executive Officer of MediBuddy, a role he has held for almost two years. MediBuddy is the award-winning, cashless technology platform from Medi Assist that has transformed the concept of a health insurance company at the very core. With diverse offerings for various stakeholders within the health benefits industry, MediBuddy allows the process of discovering, accessing, utilizing, and monitoring health benefits to be seamless, and virtually paperless. Jhaveri ascended to the top position after two years as the company’s chief business officer. Prior to his time at MediBuddy, Jhaveri worked at the award-winning Medi Assist India for five years, where he was the vice president of strategy and business planning before becoming head of products and strategy. During his time there he provided strategic direction for future initiatives and businesses for the company, including overseeing partner connect programs and relations with corporate customers, brokers, and hospitals. He joined Medi Assist from Reliance Health Ventures, where he served for five years in the Strategy & Investments department. Jhaveri acquired his Master of Business Administration degree from the Pennsylvania State University. Location: Hangzhou-Shaoxing, China Jin Zhang is the Co-Founder and Chief Executive Officer of DXY, a social media platform focused on pharmaceuticals and life sciences that today is the world’s largest online professional community of physicians, medical institutions, healthcare providers, and life science researchers. Zhang co-founded the company in 2000 alongside Tiantian Li with a mission to facilitate communication, information sharing, and collaboration among medical professionals within all specialties of clinical medicine, basic medical research, life sciences, and pharmaceutical sciences. The company has raised over $182 million over four funding rounds since its inception. Zhang has been the CEO since 2008, and today, the company has 4 million users subscribed to its platform. Under Zhang’s vision and leadership, his platform has benefited the medical industry by providing physicians with insight from colleagues and the ability to discuss new clinical findings. His platform also offers news on clinical progress and the industry at large, providing materials for physicians’ education along with its recruitment and biomedical e-commerce platforms. Prior to DXY, Zhang was an attending physician at Zhejiang University for almost four years. He acquired his Bachelor of Psychiatry degree and Doctor of Medicine degree in Neurology from Central South University. Location: Tokyo, Japan An innovator in the health space, Toru Nishikawa is the Co-founder and Chief Executive Officer of Preferred Networks, a company that implements deep intelligence throughout the internet to integrate data from the physical and digital worlds. Using real-time machine learning technologies, Preferred Networks connects with new applications in the emerging field of the Internet of Things. Founded in 2014, the company is also engaged in the research, development, and sales of computer software, hardware, and network aspects while solving problems in the areas of data analytics, edge-heavy computing, distributed intelligence, machine learning, deep learning, and computer vision activities. Serving retail, automobile, healthcare, advertising, life sciences, public safety, and other areas, the company was valued at $2 billion in 2017. Prior to funding Preferred Networks, Nishikawa worked at Preferred Networks’ predecessor, Preferred Infrastructure, Inc., which he also co-founded in 2006 while he was still in graduate school. There he led software development for information search, natural language processing, and machine learning. Nishikawa is an ICPC and ACM Programming Contest World Finalist. He also received the 2013 Software Japan Award of the Information Processing Society of Japan. He received his Master of Science degree from the University of Tokyo. Location: Sydney, Australia (Asia-Pacific) Colin Denver is the Chief Executive Officer of SpeeDx, a developer and provider of molecular diagnostic systems. Founded in 2009, SpeeDx manufactures tests for detecting infections and identifying antibiotic resistance. The company’s product portfolio focuses on multiplex diagnostics for sexually transmitted infections (STIs), antibiotic resistance markers, and respiratory diseases. Additionally, the company provides several related software and technology products geared toward various medical practices. Denver’s career with SpeeDx began as VP of sales and marketing, where he oversaw product promotion and license agreements. Now as CEO, he manages the company’s expansion into global markets across Asia-Pacific, Europe, and the U.S. Denver boasts over 20 years of experience in the life science and diagnostics market, spending over a decade as a sales director for both Bioline and Meridian Bioscience, which was acquired by Bioline in 2012. He holds a Bachelor of Science degree in biology from Pepperdine University and a post-graduate management diploma from the Macquarie University School of Business. Location: Guangdong, China Michelle Xia is the Chief Executive Officer of Akeso Biopharma, a Chinese biotechnology and pharmaceutical company. Among its array of products and services, Akeso is researching and developing innovative antibody therapies for autoimmune diseases, cancers, and more. Before Xia founded Akeso in 2012, she served as a senior vice president for Crown Bioscience, where she assembled the workforce, led platform construction, and helped form the company’s joint venture with Pfizer. Before ascending to the executive echelon, Xia worked as a senior scientist for PDL Biopharma as well as Bayer Healthcare, where she oversaw chemistry, manufacturing, and control. Additionally, she has been an active participant in innovative research programs at the University of Louisville in the U.S. and the University of Glasgow in the U.K., developing effective antibody therapies. Xia is a decorated scholar and earned a Bachelor of Science degree in biochemistry from Sun Yat-Sen University in China, and her PhD in molecular biology and microbiology from Newcastle University in the U.K. Location: Pune, India Dr. Mukesh Parmar is the Chief Executive Officer of Docplexus, which is India’s largest and leading online community of legitimate and verified clinicians of all specialties, providing them a platform for professional collaboration, research publication, and information sharing. Docplexus is also a partner with Germany-based healthcare network Coliquio and Latin America-based DocRed, expanding its reach to over 600,000 medical professionals globally. Founded in 2013, Docplexus is now experiencing an unprecedented technological and AI-backed revamp along with a cultural transformation under the multi-dimensional leadership of Dr. Parmar, who joined in January 2020. Being a surgeon, marketer, strategist and a seasoned business leader with a knack for innovation and meticulous turnaround, Dr. Parmar has managed to double the revenue growth organically and the team is all set for an international expansion with his futuristic vision and his belief in the power of people. Prior to becoming a healthcare business professional, Dr. Parmar began his career as a surgeon, an experience that still informs his decisions today and a skill that he continues to use to treat patients from lower socioeconomic strata in a nonprofit setup. He has made remarkable contributions during his management stints with large enterprises such as Johnson & Johnson and Smith & Nephew, where he oversaw marketing, strategy and business development for the Indian and international markets. In his free time, he is an avid adventure sports enthusiast, a passionate dancer-choreographer and a volunteer educator of underprivileged youth in Mumbai. Location: Hong Kong Island, Hong Kong A powerhouse leader, Avi Lasarow is the Chief Executive Officer of Prenetics International, a company with a joint mission to use genetics to transform the health and wellness outlook for millions of people. Prenetics operates under a clear mission to reduce and prevent lifestyle-related health conditions so that everyone can live longer, healthier, and happier lives. Today Prenetics is touted as a trusted choice for COVID-19 testing solutions. At Prenetics, Lasarow’s passion for innovation within science enables him to steer the company to achieve his mission of extracting cutting-edge science from laboratories to make it both accessible and understandable for people all over the world. With over 25 years in the business relentlessly pursuing science and technological innovation, Lasarow is an Honourable Consul for The Republic of South Africa—a position he has held for over nine years. A pioneer driven to humanize science, he was the founder and CEO of several companies including Prenetics’ DNAfit (where he still presides), and Trimega Laboratories. He was previously a managing director for DNA Bioscience and was also an assistant vice president at Citibank for four years. A visionary and driven leader, Lasarow’s career is linked by a singular goal to make DNA results more accessible so that thousands of people across the world can live healthier lives as a result. Location: Shanghai, China Li Chen is the Chief Executive Officer and Founder of Hua Medicine, a clinical-stage drug development company based in Shanghai, China. Founded in 2011, Hua Medicine is an innovative biotech enterprise specializing in treatments for diabetes and central nervous system disorders. In addition to serving as CEO, Chen is Hua Medicine’s Chief Scientific Officer, overseeing the R&D of its medical breakthroughs and collaborations. As both an executive and a research scientist, his operating principles include high standards and quality, and creating greater value. Chen’s career began in 1992 as an R&D scientist and medicinal chemist with Roche Pharmaceuticals, where he spent nearly two decades, eventually serving as chief scientific officer. He established Hua Medicine hoping to innovate drug development for genetic, lifestyle, and environmental diseases, which affect China and beyond. Chen holds a PhD in organic chemistry from Iowa State University and is an author of over 60 medical publications. Location: Biopolis, Singapore Silviu Itescu is the Chief Executive Officer, Executive Director, and Founder of Mesoblast, the regenerative medicine company providing treatments for inflammatory ailments, cardiovascular disease, and back pain. Founded in 2004, Mesoblast was already worth $2 billion only eight years later in 2012. Itescu is known as a master of stakeholder relations alongside his international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. Today, Mesoblast is using its proprietary technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care and where inflammation plays a central role. In addition to his role at Mesoblast, Itescu is also a faculty member at Columbia University in New York, and Melbourne and Monash Universities in Australia. He has consulted at many international pharmaceutical companies, been an advisor to biotechnology and healthcare investor groups, and has served on the board of directors for various publicly listed life sciences companies. A highly esteemed leader in the field, Itescu is the recipient of many honors and awards including being named BioSpectrum Asia’s Person of the Year in 2011. He also received the inaugural Key Innovator Award from the Vatican’s Pontifical Council for Culture for his leadership in translational science and clinical medicine in relation to adult stem cell therapy in 2013. Location: Hangzhou, China Sudhir Srivastava is the Chief Executive Officer of SS Innovations, a medical technology company based in Hangzhou, China. Founded in 2016, SS Innovations is a global pioneer in medical robotics technologies, 3D visualization systems, and advanced medical workspaces. As a surgeon, Srivastava is a premier expert in the field of robotic cardiac procedures and has performed such operations more than any other doctor worldwide. His company has made notable advancements in the design and development of multi-arm surgical robotics systems and is currently refining its technologies. Srivastava was one of 11 physicians who founded Alliance Hospital LTD in Odessa, Texas, and he served as chairman from its founding in 2003 until 2007. As a physician and as an executive, his goals are to provide educational opportunities to other doctors, make advanced robotic surgery available to more patients, and pursue cutting-edge advancements in the field. He studied at JLN Medical College in Ajmer, India, as well as at the University of British Columbia. Location: Seoul, South Korea Minhong Jang is the Co-founder and Chief Business Officer for Lunit, a company that develops advanced medical image analytics and data-driven imaging biomarkers. Founded in 2013, Lunit has been internationally acknowledged for its advanced, state-of-the-art technology and its application in medical images. Its name comes from an abbreviation of “learning unit providing medical AI software,” and the company has stayed true to that objective. Under Jang’s leadership, the company particularly focuses on tackling cancer as a leading cause of death. Prior to Lunit, Jang spent just under a decade escalating up the corporate ladder, gaining experience at various businesses across Seoul. Upon graduating, Jang started as an intern for Korn Ferry. He then moved on to being a research associate for Arthur D. Little. Following this, he was a business analyst for Ticket Monster Inc., before becoming a research associate for InBody for three years. Before co-founding Lunit, Jang worked as an Advisor for Cldi Inc. for almost two years. Over a relatively short career, Jang has scaled great heights to attain his current standing with Lunit. Jang acquired a Bachelor of Science degree in materials science and a Master of Science degree in business administration and management from the Korea Advanced Institute of Science and Technology. Location: Shanghai, China A formidable medical leader with an extensive background in the industry, Jingsong Wang is the Founder, Chairman, and Chief Executive Officer at Harbour BioMed, a role he has held for four years. Harbour BioMed is the global, clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics in the areas of oncology and immunological diseases to address unmet patient needs. With over 30 years’ experience in the field, Wang is known as a strategic and outcome-driven pharmaceutical executive with extensive exposure to a broad spectrum of R&D activities, having worked across the U.S. and China. Across his impressive career, Wang has effectively developed and managed strong cross-functional teams across multiple therapeutic areas to deliver innovative healthcare solutions for patients in China and worldwide. Currently, he is also a Member of the Board of Directors for Frontage Holdings Corporation, as well as being a Board Member for Silicon Therapeutics. He is also currently an Advisor for ACCESS Health International, as well as remaining as an Adjunct Assistant Professor of Medicine at the University of Pennsylvania School of Medicine. In his career, he has been a medical leader for a host of medical companies and has sat on multiple boards. He has been an attending physician for multiple hospitals in the U.S. as well as an ongoing instructor at various universities, including Harvard. Wang acquired his PhD in molecular pharmacology from China Pharmaceutical University. Location: Mumbai, India Shailesh Prithani is the Co-founder and Chief Executive Officer of Doxper, the company digitizing healthcare documentation across India. With a goal to be present “wherever pen touches paper in healthcare,” Doxper assists doctors and hospitals in digitizing their work and data in order to improve their operational, clinical, and patient engagement outcomes, with a long-term goal of utilizing that data to empower providers to optimize their services. As the CEO of Doxper, Prithani spearheads strategy, finance, and business development, setting the overarching direction and vision for Doxper with almost two decades of experience. Prior to founding Doxper in 2015, Prithani worked at Schlumberger. There he spent a decade in various roles ascending from field engineer to being a location manager at the time of his exit. During his tenure, Prithani led large-scale operations, sales organizations, operations support functions, and human resources gaining a host of experience in leadership that informs his expertise at Doxper. Prithani earned his Bachelor of Science degree in computer science engineering from the Indian Institute of Technology, Roorkee. Location: Woodlands Bizhub, Singapore Daniel Carraway is currently the Co-Founder and Chief Executive Officer of RWDC Industries, the company with a mission to replace petroleum-derived materials with safe, sustainable alternatives. Based in Singapore and the U.S., RWDC Industries is known for its ability to harness nature to produce the materials we use in our daily lives. The company was co-founded with Roland Wee and has recently raised $133 million in funding to build a new sustainable manufacturing juggernaut in Athens, Georgia. With bioplastics representing a $95 million opportunity, and plastic packaging being a $234.1 billion industry, Carraway’s intention to replace the plastic packaging industry with sustainable alternatives is no doubt a pursuit to watch. Having spent his career working in paper and bioplastics, Carraway started his career at International Paper, working in their research division. After his tenure there, he exited to found two companies that are credited as being the cornerstones of the bioplastics industries: Danimer Scientific (founded in 2004) and Meredian Holdings Group (founded in 2007). Carraway acquired a PhD in biotechnology from the University of Georgia.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Akeso Biopharma

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Akeso Biopharma in 1 CB Insights research brief, most recently on Nov 6, 2019.

Expert Collections containing Akeso Biopharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Akeso Biopharma is included in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

B

Biopharmaceuticals

5,881 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Akeso Biopharma Patents

Akeso Biopharma has filed 9 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Monoclonal antibodies
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/28/2018

8/31/2021

Clusters of differentiation, Monoclonal antibodies, Immune system, Immunology, Monoclonal antibodies for tumors

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

9/28/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

8/31/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Clusters of differentiation, Monoclonal antibodies, Immune system, Immunology, Monoclonal antibodies for tumors

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Akeso Biopharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Akeso Biopharma Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.